Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NWAV $ENDV $NWBO New BUY/SELL Rating issued May 11th 2017: SELL
$MJTK $PPHM $BRNE New BUY/SELL Rating issued May 11th 2017: BUY
$MMEX $AMFE $SFOR New BUY/SELL Rating issued May 11th 2017: SELL
$LQMT $GBHL $FNMA New BUY/SELL Rating issued May 11th 2017: SELL
$ELTP $CTIX $WMIH New BUY/SELL Rating issued May 11th 2017: BUY
$AVXL $PGPM $OWCP New BUY/SELL Rating issued May 11th 2017: SELL
$USRM $BLDV $DBMM New BUY/SELL Rating issued May 11th 2017: SELL
$AMLH $BVTK $DOLV New BUY/SELL Rating issued May 11th 2017: BUY
BWMG Brownies Marine Group THE MOST UNDERVALUED OTC STOCK
Today's MOST UNDERVALUED OTC Stock is Brownie's Marine Group (BWMG), profitable for 3 years in a row now, millions in revenues with heavy INSIDER accumulation!
Brownie's Marine Group, Inc. (BWMG)
Soon to be the #1 Penny Stock in America
NOW is the time to buy shares of BWMG, it is the MOST UNDERVALUED OTC stock!
It is super rare for a stock to have more cash and more profits per year than market cap.
Yet this is what has been happening to BWMG the last couple of years!
This is VERY GOOD though for investors, the share price is forecast to skyrocket as the company continues to experience explosive growth!
The water sports industry is forecast to grow at double digit rates through 2021.
Brownie's Marine Group (BWMG) is the World leader when it comes to water sports! From snorkeling to diving and everything in between BWMG and it's patented proprietary technologies have set the benchmark and are now regarded as the standard in the industry!
BUT IT GETS EVEN BETTER
More about Brownie’s Marine Group (BWMG)
Check out the companies AWESOME WEBSITE: http://www.browniesdiving.com/
BWMG does business through its wholly owned subsidiary, Trebor Industries, Inc.
It is the world’s leading innovator, designer and manufacturer of surface supplied air diving systems – often referred to as Hookah diving systems though they name their Hookah diving system the "Brownie’s Third Lung."
The Company designs, tests, manufactures and distributes recreational hookah diving, yacht based scuba air compressor and Nitrox Generation Systems, and scuba and water safety products. BWMG sells its products both on a wholesale and retail basis
The Company holds more than ten patents and enjoys a robust product development and intellectual property program that has yielded several proprietary products. Many of these products and innovations have become the “standard” for the marine industry. Brownie’s is known as the market leader when it comes to surface supplied “Third Lung” dive systems and Scuba Tankfill Systems for yacht-based diving. Brownie’s Third Lung and the Halcyon HDV underwater propulsion vehicles have been featured on Discovery Velocity Channel
$INMG $MFST $ONCI New BUY/SELL Rating issued May 10th 2017: BUY
$IBRC $FNHI New BUY/SELL Rating issued May 10th 2017: SELL
$SPCL $NWAV $CUBV New BUY/SELL Rating issued May 10th 2017: SELL
$ADXS $RSII $DEWM New BUY/SELL Rating issued May 10th 2017: BUY
$BLTA $VDRM $IHSI New BUY/SELL Rating issued May 10th 2017: BUY
$GIGL $BIEI $PPHM New BUY/SELL Rating issued May 10th 2017: BUY
$MYDX $ELTZ $TITXF New BUY/SELL Rating issued May 10th 2017: SELL
$ENDV $ETBI $DBMM New BUY/SELL Rating issued May 10th 2017: SELL
$EFLN $NSAV $ACGX New BUY/SELL Rating issued May 10th 2017: BUY
$AVXL $CTIX $WMIH New BUY/SELL Rating issued May 10th 2017: BUY
$OWCP $LQMT $ASTI New BUY/SELL Rating issued May 10th 2017: SELL
$ELTP $MJTK $SFOR New BUY/SELL Rating issued May 10th 2017: BUY
$FNMA $AMFE $ORRV New BUY/SELL Rating issued May 10th 2017: SELL
$USRM $MMEX $PGPM New BUY/SELL Rating issued May 10th 2017: BUY
$AMLH $BLDV $ICNB New BUY/SELL Rating issued May 10th 2017: SELL
$DOLV $BVTK $GBHL New BUY/SELL Rating issued May 10th 2017: BUY
CES Synergies (CESX) is The MOST UNDERVALUED stock on the OTC today!
With an amazing customer base that includes NASA, The State of Florida and The US Dept. of Defense! With millions and millions in revenues and expansion plans across the nation CESX is well on it's way to becoming one of the largest Environmental Contracting and Demolition companies in the nation!
Soon to be the #1 Penny Stock in America!
NOW is the time to buy shares of CESX, it is the MOST UNDERVALUED stock on any market!
BUT IT GETS EVEN BETTER
Just look at some of their AWESOME CUSTOMERS
many providing re-occurring revenue for CESX
CESX Diverse Customer Base
ABOUT CES Synergies (CESX)
The MOST UNDERVALUED stock on the OTC today: CES Synergies (CESX), with an amazing customer base that includes NASA, The State of Florida and The US Dept. of Defense! With millions and millions in revenues and expansion plans across the nation CESX is well on it's way to becoming one of the largest Environmental Contracting and Demolition companies in the nation!
***It is projected that CESX will sign over 150 NEW CONTRACTS in 2017***
That's roughly one new contract every 3 days!
INCREDIBLE that this is trading at 2 cents with only 47M O/S (remember INSIDERS own 82%), NOW you see just how EXTREMELY undervalued CES Synergies (CESX) is!
The Company provides asbestos abatement and removal, demolition, and mold remediation services primarily in the USA. The services provided include the removal of asbestos, lead and other hazardous materials from structures ranging from residences to commercial and industrial applications, including secure defense contractor facilities, colleges, hospitals, and mid-rise and high-rise buildings and residential structures. In the public sector, customers include city, state, and federal agencies. Private-sector customers include general contractors, developers, project owners, and industrial and commercial clients.
Check out CESX awesome website www.crossenv.com/
CESX is expanding to become one of the largest Environmental Contracting and Demolition companies in the nation!
Business is booming for CESX
***It is projected that CESX will sign over 150 NEW CONTRACTS in 2017***
That's roughly one new contract every 3 days!
INCREDIBLE that this is trading at 2 cents with only 47M O/S (remember INSIDERS own 82%), NOW you see just how EXTREMELY undervalued CES Synergies (CESX) is!
Here are just TWO EXAMPLES of CESX contracts already signed with the US Dept of Defense
BUT IT GETS EVEN BETTER
CES Synergies (CESX) is also in discussions to acquire SIX other companies who operate in the same sector!
Names cannot yet be revealed due to non disclosure agreements, but the company has given us this general outline:
The MOST UNDERVALUED stock on the OTC today: CES Synergies (CESX), with an amazing customer base that includes NASA, The State of Florida and The US Dept. of Defense! With millions and millions in revenues and expansion plans across the nation CESX is well on it's way to becoming one of the largest Environmental Contracting and Demolition companies in the nation!
***It is projected that CESX will sign over 150 NEW CONTRACTS in 2017***
That's roughly one new contract every 3 days!
INCREDIBLE that this is trading at 2 cents with only 47M O/S (remember INSIDERS own 82%), NOW you see just how EXTREMELY undervalued CES Synergies (CESX) is!
$NMUS $INOH New BUY/SELL Rating issued May 8th 2017: BUY
$ACGX $ADXS $SPCL New BUY/SELL Rating issued May 8th 2017: BUY
$TRTC $NWAV $FNBC New BUY/SELL Rating issued May 8th 2017: BUY
$AUPH $CEGX $VPOR New BUY/SELL Rating issued May 8th 2017: SELL
$MJTK $RSII $BLTA New BUY/SELL Rating issued May 8th 2017: BUY
$IBRC $ENDV $NOHO New BUY/SELL Rating issued May 8th 2017: SELL
$PPHM $ELTZ $ORRV New BUY/SELL Rating issued May 8th 2017: SELL
$GIGL $EFLN $CUBV New BUY/SELL Rating issued May 8th 2017: BUY
$CTIX $HHSE $EEGI New BUY/SELL Rating issued May 8th 2017: SELL
$AMRN $WMIH $MYDX New BUY/SELL Rating issued May 8th 2017: SELL
$SFOR $ELTP $ABHI New BUY/SELL Rating issued May 8th 2017: BUY
$DBMM $ETBI $NSAV New BUY/SELL Rating issued May 8th 2017: SELL
$AVXL $PGPM $NWBO New BUY/SELL Rating issued May 8th 2017: BUY
$USRM $MMEX $FNMA New BUY/SELL Rating issued May 8th 2017: SELL
$LQMT $ICNB $OWCP New BUY/SELL Rating issued May 8th 2017: SELL
$BVTK $BLDV $AMFE New BUY/SELL Rating issued May 8th 2017: BUY
$DOLV $AMLH $GBHL New BUY/SELL Rating issued May 8th 2017: SELL
Today's FEATURED most UNDERVALUED OTC stock is biotech LCAR
The MOST UNDERVALUED stock on the OTC today is a small biotech: Lescarden Inc. (LCAR), it's lead product CATRIX has been approved by the FDA and is in demand!
Lescarden (LCAR) is a small biotech company that is a leader in the $17 BILLION Wound Care sector. Their lead product, Catrix is patented and has been approved by the EU and the FDA to treat chronic wounds, severe burns and multiple other applications!
Clinical and laboratory studies also point to Catrix as a potential agent for the treatment of certain cancers!
Lescarden (LCAR) is now believed to be in buyout discussions with British based BIG PHARMA Smith and Nephew who have operations in over 100 countries!
Smith and Nephew is one of the leading BIG PHARMA's investing in acquiring small Wound Care biotechs, and have already signed a licensing agreement with Lescarden (LCAR) for the distribution of Catrix in the Spain!
Lescarden (LCAR) also has signed an exclusive license agreement with Daewoong Pharmaceuticals, headquartered in Seoul, South Korea. Daewoong is the largest producer and marketer of over-the counter and ethical pharmaceutical products in Korea, with annual sales over $400 million. Already established in the diabetic foot ulcer segment of the market, Daewoong is expanding its product line to cover all aspects of wound treatment. This brings added value to any acquisition discussions with Smith and Nephew who would then increase their footprint in Asia!
Right now the hottest merger and acquisition sector in the biotech industry is Wound Care and the buyout rate of small biotech companies specializing in Wound Care is forecast to increase in 2017. The global market for Wound Care is projected to top $20 BILLION by 2021!
Lescarden (LCAR) already has a huge edge over many competitors, it has gone from FDA and EU approval to commercializing Catrix and has begun to set record revenues.
For the nine months ended February 28, 2017 compared to February 28, 2016 revenues increased by 270% approaching half a million dollars. Sales would have been even higher but supply issues led to the delayed shipment of Catrix to Smith and Nephew!
Lescarden (LCAR), trading at 2 cents a share is going to get snapped up! Just read below all the buyouts and acquisitions that have been occurring in the previously overlooked wound care sector!
LCAR's Catrix is an amazing product, when applied directly to non-healing wounds, such as debubitus ulcers (bedsores), diabetic ulcers, and venous ulcers, Catrix Wound Dressing actually accelerates the healing process, effectively closing the wounds while minimizing scarring.
In studies performed on wounds that had previously failed to respond to months of standard wound healing treatment, dramatic improvements were seen in just seven weeks!
BUT IT GETS EVEN BETTER
Clinical and laboratory studies also point to Catrix as a potential agent for the treatment of certain cancers!
Lescarden (LCAR) also has 2 other products that have been commercialized:
-Poly-NAG in the anti-arthritic market as a treatment for osteoarthritis. Clinical trials were so successful that both the US and EU awarded patents to Lescarden (LCAR)! This is a huge market with North American sales of anti-arthritic remedies are over $400 million annually.
-Bio-Cartilage, a pure Bovine Tracheal Cartilage supplement used for the potential treatment for certain types of cancer, Inflammatory Joint Disease and as a immune system enhancer.
Lescarden (LCAR) is EXTREMELY UNDERVALUED, trading near historic lows around 2 cents a share and UNDER THE RADAR!
Now is the time to BUY shares of Lescarden (LCAR)
LCAR has a tiny share structure with only 63M O/S of which INSIDERS own 22M, the float is a mere 16M shares.
(This means that the share price could rise very quickly with limited shares available!)
WOUND CARE is now HUGE business for pharmaceutical companies!
What makes Lescarden Inc. (LCAR) so attractive is that big pharmaceutical companies have until recently overlooked the wound care market. In the last few years a spate of buyouts and acquisitions has begun as BIG PHARMAS start to scoop up smaller players.
NOW is the time to buy shares of tiny LCAR, they will be acquired by the end of 2017!
Just look at these HEADLINE clips:
Overlooked Advanced Wound Care Market Catches Attention of Healthcare Analysts, Investors
Predictably, several healthcare analysts and some savvy investors have started paying attention to this niche market.
There are about 50 million reported cases globally of patients suffering from hard-to-close wounds, according to published reports, including some 15% of diabetic foot ulcers in the U.S. that eventually required amputations are creating a compelling product offering for healthcare professionals treating the 900,000 diabetic foot ulcers each year!
Wound Care Is "Big Business" Both large pharmaceutical companies and device companies have realized that wound care is big business, For example, wound bandages and dressings are a $2 billion business in the USA, he said. Smith & Nephew and Johnson & Johnson have been among the first major pharmaceutical companies to recognise the potential of the wound care market
The global wound care market is expected to reach USD 20.4 Billion by 2021 from USD 17.0 Billion in 2016, growing at a CAGR of 3.6% from 2016 to 2021.
The advanced wound management product segment commanded the largest share in 2015, and is forecast to be the fastest-growing segment in the wound care market. Factors such as rising awareness regarding new technologies for wound care, government support in the form of funding, and rising diabetic and aging population are driving the growth of the wound care market.
The prominent players in the wound care market are 3M Company (U.S.), Baxter International, Inc. (U.S.), Coloplast A/S (Denmark.), Convatec Healthcare B.S.A.R.L (U.S.), Covidien PLC (Ireland), Derma Sciences, Inc. (U.S.), Ethicon, Inc. (U.S.), Hollister, Inc. (U.S.), Kinetic Concept, Inc. (U.S.), Mölnlycke Health Care (Sweden), and Smith & Nephew (U.K.).
MORE ABOUT Lescarden Inc. (LCAR)
Lescarden Incorporated is a biotechnology company dedicated to the research and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, autoimmune and cancer applications!
Years of product testing and refinement has led to the creation of Lescarden’s proprietary formula for purifying bovine cartilage producing a sterile white powder that optimizes the healing and anti-inflammatory processes. Today, the company’s exclusive bovine cartilage powder, marketed as Catrix®, is FDA and EU approved for the management of chronic wounds and severe burns.
Clinical and laboratory studies point to Catrix as a potential agent for the treatment of certain cancers.
The cornerstone of the Catrix product line, Catrix Wound Dressing is renowned for its superior healing characteristics.
Catrix Wound Dressing is a natural, biodegradable product, made from a specially processed bovine cartilage in the form of a fine white powder. Catrix has no chemical additives.
When applied directly to non-healing wounds, such as debubitus ulcers (bedsores), diabetic ulcers, and venous ulcers, Catrix Wound Dressing actually accelerates the healing process, effectively closing the wounds while minimizing scarring.
In studies performed on wounds that had previously failed to respond to months of standard wound healing treatment, dramatic improvements were seen in just seven weeks!
FDA-cleared for multiple healing applications
Catrix Wound Dressing is cleared for use by the Food and Drug Administration and is EU-certified for the management of:
Pressure ulcers (stages I-IV)
Stasis ulcers
1st and 2nd degree burns
Diabetic ulcers
Post-surgical incisions
Radiation dermatitis
Cuts, abrasions and irritations
Partial thickness wounds
Skin conditions associated with peristomal care
How Catrix Wound Dressing works
The unique properties Catrix Wound Dressing work with the body’s own healing capabilities to effectively close wounds. Catrix stimulates granulation within the wound, establishing a matrix that induces the development of the necessary components (connective tissue, skin, blood vessels) needed to heal. Containing 50% micronized collagen, Catrix Wound Dressing accelerates the biological process of reparation by activating the following processes:
Attracts fibroblasts – encourages production of connective tissue
Activates macrophages – stimulates formation of blood vessels
Stimulates growth of fibroblastes (12%) and keratinocytes (40%)
Stimulates growth fibroblasts and keratinocytes
Increases scar strength (resistance of the wound to tearing) by 50%
The result is a wound that heals rapidly, displays better quality of granulation and vascularization tissue, and a scar that is more aesthetic with superior tensile strength at every stage of its
subsequent recovery.
Advantages of Catrix Wound Dressing
Biodegradable - does not need to be removed from the wound
Completely absorbed at seven days
Compatible with gauzes and with moist applications
Can absorb exudate up to 10 times its weight
Controls excess exudates. Keeps the bed of the wound moist
Has a barrier effect – protects against infection
Does not harm the skin around the ulcer
Application is painless
Reduces bleeding
Has no adverse effects
Good for patients and the healthcare system
Catrix Wound Dressing offers important benefits to patients and healthcare providers:
Accelerated healing of wounds - leads to increased patient comfort, improved quality of life, and reduced chance of accidental infection
Decreased treatment cost - dramatic savings through reduced staff required to treat wounds, lower material cost per treatment, and shortened term of treatment required for full recovery
Simple, convenient application available in single-use foil packets - Catrix Wound Dressing is sprinkled directly from the packet onto the wound - makes it ideal for use in hospitals, extended care facilities and at-home care
Catrix Wound Dressing is packaged in cartons of 14 and 7, one-gram foil packets.
SUMMARY
Now is the time to buy shares of Lescarden (LCAR) BEFORE it gets acquired by a Smith and Nephew.
LCAR is ridiculously undervalued having an FDA and EU approved, patented and commercialized WOUND CARE product that is incredibly effective!
Good call on $OMVS monster nvsos update found today for the merger or acquisition or RAD
$VDRM New BUY/SELL Rating issued May 5th 2017: BUY
$COTE New BUY/SELL Rating issued May 5th 2017: BUY
$ELED New BUY/SELL Rating issued May 5th 2017: SELL
$RDAR New BUY/SELL Rating issued May 5th 2017: SELL
Followers
|
10
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
213
|
Created
|
05/03/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |